32 results
8-K
EX-99.1
GOSS
Gossamer Bio Inc
20 Jul 23
Interim TORREY OLE Update and PROSERA Phase 3 Design July 2023
7:50am
of effect in Phase 3 target population Attractive safety profile for chronic treatment Regulatory feedback supportive of single registrational study … chronic treatment in PAH patients Reports of cough diminish as patients get used to DPI Vast majority of patients have reached and maintained 90mg BID
8-K
EX-99.1
GOSS
Gossamer Bio Inc
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
Exhibit 99.1
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
- Primary endpoint … , respectively; 23% improvement observed in 40 mg group -
- TITAN Study in chronic rhinosinusitis did not meet primary or secondary endpoints
8-K
v29a rm22smd916
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
8-K
EX-99.2
vnn0ynporj7bkwk
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
8-K
EX-99.1
ob0o 95fyw212
11 Aug 20
Gossamer Bio Announces Second Quarter 2020 Financial Results and Provides Corporate Update
4:30pm
424B5
rlp375yhbp7
19 May 20
Prospectus supplement for primary offering
5:11pm
424B5
swqt3 xloe89epfl
19 May 20
Prospectus supplement for primary offering
5:08pm
424B5
jkx2rrhyd 5tt1mkcg
18 May 20
Prospectus supplement for primary offering
4:16pm
424B5
dk52irp 6q
18 May 20
Prospectus supplement for primary offering
4:11pm
8-K
EX-99.1
5pgny7 ah3dj77wx59
12 May 20
Gossamer Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update
4:18pm
8-K
EX-99.1
u83a ja6259v
24 Mar 20
Gossamer Bio Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
8:45am
8-K
EX-99.1
igyt7ll dpmmaxl
12 Nov 19
Gossamer Bio Announces Third Quarter 2019 Financial Results
4:10pm